- Types of Eczema
- Child Eczema
- Causes & Triggers
- Living with Eczema
- Eczema Products
- Get Involved
February 21, 2017 — There are dozens of new drugs in development for atopic dermatitis (AD). Late last year, the Food and Drug Administration (FDA) approved the non-steroidal topical treatment, Eucrisa for mild to moderate atopic dermatitis. This March, the FDA is expected to approve dupilumab, the first biologic drug for adults with moderate to […]
January 17, 2017 — Biologic drugs have been making headlines as potentially promising new therapies for treating atopic dermatitis (AD). Several have shown positive results in clinical trials and one, dupilumab, is being reviewed for approval by the Food and Drug Administration (FDA) and is expected to come to market in 2017. Biologic medications are […]
December 14, 2016 — People with atopic dermatitis have a new treatment option. Today, the U.S. Food and Drug Administration approved Eucrisa (crisaborole), a topical treatment for children and adults with mild to moderate atopic dermatitis (AD). Eucrisa works differently than other topical treatments on the market. It is not a steroid or a topical […]
October 18, 2016 – For the first time in decades, new drugs and therapies that may provide real relief for anyone living with eczema are close to being available. For many, this is a time of unprecedented hope. But what if there were a way to prevent the very first flare, to stop eczema from even starting? Frustrated by […]
What you need to know August 18, 2016 — Finding a treatment that works for your eczema or atopic dermatitis (AD) symptoms can feel like an endless cycle for some people. And it’s not just about finding the right medicine, but about getting it covered by your health plan as well. It’s hard enough when […]
June 9, 2016 – On Monday, June 6, 2016 the pharmaceutical companies Regeneron and Sanofi, reported positive results for the Phase 3 the clinical trial of the new biologic drug, dupilumab, when used in conjunction with a topical corticosteroid by adults to treat moderate-to-severe atopic dermatitis (AD).
We all play an important role, especially patients, in bringing new treatments to those that need them. Research is like a relay race that scientists can only take so far, and at some point, they must hand the baton to patients to engage in clinical trials to help bring the treatment to reality. The National […]
February 10, 2016 – In January, Anacor Pharmaceuticals, Inc. announced that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of crisaborole topical ointment, 2%.